A Victory for Patients

Today, the Oncology Drug Advisory Board to the FDA recommended approval for the drug pralatrexate, a treatment for patients with relapsed or refractory peripheral T-Cell lymphoma.  Following a 10-4 vote in favor of approval the FDA will make the final decision on approval September 24th.

Pralatrexate was discovered at Memorial Sloan Cancer Center in New York and later in-licensed by Allos in 2002 during my tenure as CEO.  In those early years we could barely scrape enough money together to keep the development programs going, but we managed.  We had several spirited discussions at board meetings about terminating the program;  some so spirited, in fact, that they undoubtedly contributed to my ouster in early 2006.   But we persevered, all believing that one day pralatrexate could be approved.

Today’s recommendation by ODAC does not constitute approval, but it does represent a significant milestone on the path to approval.

Congratulations to the team at Allos Therapeutics and to all those who came before you and to those that fought to develop pralatrexate along the way.

UPDATE:  On September 25, 2009 the FDA approved pralatrexate, trade name Folotyn, as the first and only approved therapy for relapsed or refractory peripheral T-Cell lymphoma.

 

Share

Advertisements

About Mike

Mike has been an executive in the biotechnology industry for the past 20 years. Mike is a graduate of University of California, Santa Barbara, earning Bachelors degrees in Business Economics and Geography. Mike also earned his MBA in Finance from California State University, Fresno. Mike is married to the mother of his 3 children and currently lives outside of Boulder, CO. In his spare time Mike enjoys hiking, fishing, skiing, reading and coaching basketball.
This entry was posted in Cancer, Management and tagged , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s